Literature DB >> 9527100

Levels of soluble Fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers.

T Toyozaki1, M Hiroe, T Saito, Y Iijima, H Takano, K Hiroshima, H Kohno, S Ishiyama, F Marumo, Y Masuda, H Ohwada.   

Abstract

This study showed that serum levels of sFas were elevated in patients with myocarditis, and that this elevation was correlated with sIL-2R level as a marker of T-cell activation. Therefore, sFas levels may be associated with T-cell activation in patients with myocarditis, and elevation of sFas may inhibit apoptosis in activated T cells, leading to persistent cell-mediated destruction of myocytes in myocarditis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9527100     DOI: 10.1016/s0002-9149(97)01032-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  The impact of molecular medicine upon early cardiovascular drug development.

Authors:  M W Lunnon; M Braddock
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

2.  Soluble antiapoptotic molecules and immune activation in chronic heart failure and unstable angina pectoris.

Authors:  P Fiorina; E Astorri; R Albertini; A Secchi; A Mello; M Lanfredini; A Craveri; G Olivetti; F Quaini
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

3.  Critical role for death-receptor mediated apoptotic signaling in viral myocarditis.

Authors:  Roberta L DeBiasi; Bridget A Robinson; J Smith Leser; R Dale Brown; Carlin S Long; Penny Clarke
Journal:  J Card Fail       Date:  2010-11       Impact factor: 5.712

4.  Off-pump coronary artery bypass grafting attenuates proinflammatory markers.

Authors:  Atsushi Yamaguchi; Hidehito Endo; Koji Kawahito; Hideo Adachi; Takashi Ino
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-03

5.  Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer.

Authors:  Taofeek K Owonikoko; Mohammad S Hossain; Chandar Bhimani; Zhengjia Chen; Sungjin Kim; Suresh S Ramalingam; Shi-Yong Sun; Dong M Shin; Edmund K Waller; Fadlo R Khuri
Journal:  Cancer       Date:  2013-01-22       Impact factor: 6.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.